Scandion Oncology A/S (SCOL) Stock Statistics & Valuation Metrics

Scandion Oncology A/S has a market cap or net worth of kr2.49M. The enterprise value is -kr1.87M.

Scandion Oncology A/S has 234,761,410 shares outstanding. The number of shares has decreased by -2.65% in one year.

Scandion Oncology A/S’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Scandion Oncology A/S is -2.77. Scandion Oncology A/S’s PEG ratio is 0.06.

In the last 12 months, Scandion Oncology A/S had revenue of 0.00 and earned -39.20M in profits. Earnings per share was -0.96.

In the last 12 months, operating cash flow was -35.72M and capital expenditures 0.00, giving a free cash flow of -35.72M billion.

Scandion Oncology A/S pays an annual dividend of ―, resulting in a dividend yield of ―

Scandion Oncology A/S upcoming earnings date is May 22, 2025, TBA Not Confirmed.

Scandion Oncology A/S as a current ratio of 9.79, with Debt / Equity ratio of 0.69%

In the past 12 months, Scandion Oncology A/S has paid 5.50M in taxes.

Scandion Oncology A/S EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Scandion Oncology A/S has kr14.81M in cash and marketable securities with kr499.00K in debt, giving a net cash position of -kr14.65M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Scandion Oncology A/S is ―, which is 11.43% higher than the current price. The consensus rating is ―